Back to overview

Analyse der Anti-Tumor Immunantwort bei Patienten mit Multiplem Myelom als eine Grundlage für die Entwicklung von immuntherapeutischen Behandlungsansätzen

English title Dissecting anti-Tumor Immune Responses in Patients with Multiple Myeloma: a Basis for the Development of Immunotherapeutical Treatment Modalities
Applicant Zippelius Alfred
Number 103608
Funding scheme Project funding (Div. I-III)
Research institution Klinik und Poliklinik für Onkologie Universitätsspital Zürich
Institution of higher education University of Zurich - ZH
Main discipline Experimental Cancer Research
Start/End 01.07.2004 - 30.09.2007
Approved amount 188'135.00
Show all

Keywords (6)

multiple myeloma; CD8 T cells; NKT cells; cancer testis antigens; SEREX; effector functions

Lay Summary (English)

Lay summary
In the last decade experimental work mainly performed in melanoma has made critical advances towards understanding the magnitude and characteristics of cellular and humoral immune responses in cancer patients. The discovery of tumor antigens such as cancer testis (CT) antigens and the identification of the corresponding T cell epitopes has allowed, for the first time, not only to trace, but also to induce or augment tumor antigen-specific immune responses. The goal of this grant proposal is to contribute to the development of novel treatment modalities for multiple myeloma that will improve the prognosis of patients with this disease.
Currently, such efforts are hampered by the still incomplete view on immune mechanisms involved in myeloma rejection. In particular, it is essential for those developments (i) to assess the inherent immunogenicity of CT antigens expressed in the tumor, (ii) to further elucidate the magnitude and specificity of previously reported anti-myeloma T cell responses, (iii) to dissect mechanisms of functional tolerance active in patients with multiple myeloma, (iv) to define shared novel and potential tumor rejection antigens, and (v) to understand the immunomodulatory role of drugs that have been only recently described to be extremely effective in the treatment of multiple myeloma. To address some of these issues, we intend to undertake a three-year research program.
Direct link to Lay Summary Last update: 21.02.2013

Responsible applicant and co-applicants